Denali Therapeutics Inc (STU:4DN)
€ 21.91 +1 (+4.78%) Market Cap: 3.55 Bil Enterprise Value: 2.96 Bil PE Ratio: 0 PB Ratio: 4.91 GF Score: 39/100

Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2026 / 09:30PM GMT
Release Date Price: €15.51 (+0.78%)
Ryan Watts
Denali Therapeutics Inc - President, Chief Executive Officer, Director

Thank you, Jess. Great to be back here at JPMorgan. It's exciting, Year ahead for Denali, so I'm looking forward to presenting today and telling you about our path, to patience.

So just a reminder that we founded Denali to really deliver biotherapeutics to the brain and our adventure. Has led us to actually many regions, not just the brain but throughout the whole body with the transport vehicle technology and a lot of the data has really come, has matured over the last several years, both clinical data and pre-clinical data telling us the power of using trans receptor, to enable biotherapeutics to access the brain and beyond. It's also become a very exciting and competitive field, so it's great to see many colleagues and. And friendly competitors here today at at at JPMorgan.

So let's dive in. Today's key messages, I think importantly that we believe that the transport vehicle is one of the most validated, and differentiated and clinically proven BBB platforms, and we now are seeing we're moving our 4th

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot